{
    "nctId": "NCT03575260",
    "briefTitle": "500mg Fulvestrant Versus Exemestane in MBC",
    "officialTitle": "500mg Fulvestrant Versus Exemestane in Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-steroidal Aromatase Inhibitors in Clinical Practice- a Multicenter Retrospective Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal woman, age \\> 18 years old\n* Diagnosed with ER/PR+\uff0cHER2- Metastatic Breast Cancer\n* Adjuvant treatment of Non-steroidal Aromatase Inhibitors\n* First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01\n* Available medical history\n\nExclusion Criteria:\n\n* Incomplete medical history",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}